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Abstract
Background: Oral Graft-versus-Host Disease (oGvHD) is a common complication of haematopoietic stem cell 
transplantation. Choosing the right topical application to be used intra orally can be a challenge. Consequently, 
the aim of this work is to review the effectiveness and safety of topical agents currently used in the management 
of the inflammatory mucosal lesions encountered in oGVHD.
Material and Methods: We carried out electronic searches of publications up to May 2015 of the databases Pubmed, 
National Library of Medicine’s Medline, Embase and the Cochrane Central Register of Controlled Clinical trials 
to identify potentially relevant studies (keywords: “oral”, “graft”, “versus”, “host”, “disease” and “treatment”). 
The main inclusion criterion was the reported use of a topical agent which was not intentionally swallowed when 
used for the treatment of oGVHD. A 3-point grading system, described by the Swedish Council on Technology 
Assessment in Health Care and the Centre for Reviews and Dissemination, University of York, was used to rate 
the methodological quality of the papers.
Results: From the 902 entries identified in the search, 7 studies qualifying for inclusion were analysed. Overall, 
there is limited evidence with regards to the effectiveness of topical steroids for oGVHD. However, the studies 
showed some effect of Budesonide alone and when combined with dexamethasone. Topical tacrolimus also ap-
pears to have some effect and clobetasol propionate mouthwash had a significantly better clinical response than 
dexamethasone mouthwash in treating oGVHD. 
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Conclusions: As the number of clinical trials conducted is limited, there is little evidence to support the use of topi-
cal therapies to treat the inflammatory mucosal lesions found in oGVHD. High quality randomised control trials are 
needed in order to measure the effectiveness of any topical application for the treatment of the inflammatory mucosal 
lesions found in oGVHD.
Key words: Oral, graft versus host disease, topical, therapy.
Introduction
Graft versus host disease (GVHD) is caused by allore-
active donor T cells, which recognise and target host tis-
sues in immunocompromised recipients (1). It is a com-
mon post transplant complication which affects up to 
half of all haematopoietic stem cell transplant (HSCT) 
patients (2). The 2005 National Institute of Health 
(NIH) Consensus Conference first proposed new crite-
ria for the diagnosis of GVHD and scoring the severity 
of chronic GVHD (cGVHD). In 2014, revisions were 
made to address areas of controversy or confusion, such 
as the overlap GVHD subcategory and the distinction 
between active disease and past tissue damage (3). 
Patients with cGVHD may suffer from severe morbid-
ity, usually involving the skin, mouth, eyes, GI tract and 
liver but other systems such as the lungs, joints and gen-
itourinary tract  may also be involved (4).  The oral cavi-
ty is the second most commonly involved organ system, 
after skin involvement (4). Oral GVHD (oGVHD) can 
present as generalised mucosal erythema, erosions, ul-
cerations, white striae or papules resembling oral lichen 
planus, and the transplanted patient can also develop 
oral mucocoeles (4-6). Patients may also complain of 
xerostomia and pain (5). The use of pre-HSCT chemora-
diotherapy conditioning, post-HSCT medications or in-
fections can result in changes in the oral mucosa such as 
oral mucositis and/or result in oGVHD causing difficul-
ties for clinicians in differentiating between symptoms 
related to cGVHD and other side effects of therapy (5).
Oral GVHD can be managed with systemic therapy, 
or topical treatment alone or in combination in order to 
achieve pain control and provide local palliation (2). Sys-
temic immunosuppression can usually control the oral 
lesions of cGVHD but patients may require the use of 
opiates for the control of their pain symptoms (2). Clini-
cally, oGVHD  develops during reduction of systemi-
cally administered immunusupressants after HSCT. The 
use of topical agents to control inflammation in oGVHD 
might allow lower doses or faster reduction in the dose of 
systemically administered immunusupressants thereby 
helping to reduce the side effects of systemic therapy (2). 
We believe a review of the currently reported clinical 
studies of topical therapies used for the management of 
the inflammatory mucosal lesions found in oGVHD is 
advantageous for clinicians in secondary care, to estab-
lish the effectiveness of these therapies in the manage-
ment of this condition. Therefore, the aim of this work 
is to review the clinical effectiveness of topical interven-
tions for oGVHD and to prepare a clinical guideline for 
the management of oGVHD or to identify possible gaps 
in the evidence in order to carry out future research.
Material and Methods
A systematic review to unify and summarise the pub-
lished literature on topical agents used for the treatment 
of the inflammatory mucosal lesions found in oGVHD 
was undertaken. An electronic search of the databases 
Pubmed, National Library of Medicine’s Medline, Em-
base, Cochrane Central Register of controlled clinical 
trials and Scopus up to May 2015 was undertaken, to 
identify potentially relevant studies. The key words 
used in the search included “oral”, “graft”, “versus”, 
“host”, “disease” and “treatment”.
The inclusion criteria also included randomised con-
trolled clinical trials, cohort studies (retrospective and 
prospective), and case-controlled studies published 
in English, Portuguese and Spanish languages for the 
treatment of oGVHD presenting as inflammatory mu-
cosal conditions such as lichen planus and lichenoid 
disorders, that included clear descriptions of the topical 
therapy used and its method of application. The search 
was limited to human studies. The final criterion was 
the use of a topical application which was not inten-
tionally swallowed and was used for the treatment of 
oGVHD.  All articles which did not fit into the criteria 
were excluded, including reviews, author debates, let-
ters to the editor or studies in which it was not clear 
whether the treatment was for oGVHD or for mucositis 
secondary to chemotherapy/radiotherapy.
The full papers and abstracts identified through the 
search engines were independently reviewed by the au-
thors (RA, LM, ZK, AP, JH, SW, AR, EJS & JLL) for 
inclusion in this systematic review. If there was insuf-
ficient information provided in the abstract or if there 
was a disagreement between the reviewers, the authors 
reviewed the full text before reaching an agreement 
through discussion. 
Data extraction was then completed in duplicate by the 
same independent reviewers. The following data were 
collected: study characteristics (year, design, number 
enrolled/analysed, patient median/mean age, interven-
tion, length of follow-up and outcome). The search strat-
egy and the flow diagram of article selection are shown 
in figure 1. 
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From those studies, the methodological quality was 
reviewed as an indication of the strength of evidence 
provided by the study. Flaws in the design or in the 
conduction of the study were analysed using PRISMA 
(Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses) as well as a 3-point grading system, de-
scribed by the Swedish Council on Technology Assess-
ment in Health Care (SBU) and the Centre for Reviews 
and Dissemination, University of York (accessed 30th 
June, 2015 https://www.york.ac.uk/media/crd/System-
atic_Reviews.pdf). With regards to the grading of the 
studies, this was assessed by all of the authors and any 
inter examiner conflicts were resolved by discussion of 
each study to reach a consensus (Table 1). Other meth-
ods to appraise literature have been described with well 
known advantages and disadvantages (7).  This current 
method has been successfully used in other systematic 
reviews providing a good opportunity to assess clini-
cal trials and observational studies as reported in other 
studies (8,9).
The SBU tool permitted the assessment of the level of 
the available evidence for reports according to the fol-
lowing grading: Strong: at least two studies of level ‘A’; 
Moderate: one study of level ‘A’ and at least two studies 
of level ‘B’; Limited: at least two studies of level ‘B’;
Scarce: fewer than two studies of level ‘B’. Authors 
(ZK, EJS, JLL) prepared data extraction tables and all 
authors contributed to summary reports of the selected 
journal articles, critical appraisal and review of the lit-
erature.
 
Results
From the 7 studies listed in table 2, it is apparent that 
budesonide, dexamethasone and tacrolimus were the 
most common topical medications used in published 
studies. Of the reviewed studies, there were 2 ran-
domised clinical trials (10,11) and 5 cohort studies (12-
16). The median age, length of study, topical applica-
tion, grading and outcome for each study are reported 
in table 2. The side effects reported in each study are 
listed in table 3. 
The excluded articles were, one case series of the topi-
Fig. 1. Flow diagram of article selection.
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Grade A - high value of evidence 
All criteria should be met: 
-Randomised clinical study or a prospective study with a well-defined control group 
-Defined diagnosis and endpoints 
-Diagnostic reliability tests and reproducibility tests described 
-Blinded outcome assessment 
Grade B - moderate value of evidence 
All criteria should be met: 
-Cohort study or retrospective case series with defined control or reference group 
-Defined diagnosis and endpoints  
-Diagnostic reliability tests and reproducibility tests described 
Grade C - low value of evidence 
One or more of the conditions below: 
-Large attrition 
-Unclear diagnosis and endpoints 
-Poorly defined patient material 
Table 1. Swedish Council on Technology Assessment in Health Care.
Author/
Country/ 
Year
Sample Age (years) (median/mean) 
Length of study/ 
Follow up 
Type of study/ Grade 
(if applicable) Topical agent Outcome 
Elad et al 
Israel/Germany 
2012 
18 Median 42 8 weeks Randomised clinical trial/ Grade B 
3mg budesonide/10 ml 
mouthrinse.  
Topical budesonide 
mouthrinse improved 
oral cGVHD in all 
patients. The response 
was similar in all 
treatment arms 
Sari et al 
Turkey 
2007 
23 
Median  
Group A: 29 
Group B: 36 
Median 
Group A: 8.5 
months 
Group B: 7 
months 
Retrospective Cohort 
Grade B 
3mg budesonide 10 ml 
mouthrinse  
Topical budesonide 
might be added to 
systemic therapy to 
obtain better response 
rates in patients with 
oGVHD. 
 Park et al 
South Korea 
2013 
50 
Mean 
Group A: 5.2 
Group B: 6.2 
1 month Prospective Cohort/ Grade C 
Budesonide 0.03%, 
10ml mouthrinse vs 
dexamethasone 0.01% 
mouthrinse 5-10ml 
Decreased cGVHD 
severity and pain 
scores but no 
statistical differences 
were seen between 
both groups 
Noce et al 
Brazil 
2014 
32 Median 49.5 Median 471 days 
Randomised double-
blind clinical trial/ 
Grade B 
 
Clobetasol propionate 
0.05%, 5ml mouthrinse 
vs dexamethasone 
0.1mg/ml, 5ml 
mouthrinse  
Clobetasol was 
significantly more 
effective than 
dexamethasone 
(symptoms and 
clinical appearance of 
oral lesions) 
Mawardi et al 
USA 
2010 
14 Median 54 
Median 60 days 
 
 (first follow up 
12-49 days and 
second  follow up 
49-86 days) 
Retrospective Cohort 
Grade B 
Dexamethasone 
(0.25mg/2.5ml)/ 
Tacrolimus 
(0.25mg/2.5ml). 
(mouthrinse)  
Combined topical 
DEX/TAC therapy 
appears to be effective 
in reducing symptoms 
attributable to 
oGVHD 
Albert et al 
Germany 
2007 
6 Average10  (6-16 years of age) 16 to 354 days 
Prospective Cohort 
(children)/ Grade C 
 
Tacrolimus 0.1% 
ointment BD orally  
Topical TAC holds 
promise as a safe and 
efficacious treatment 
for oGVHD in 
children 
Epstein et al 
Canada 
1994 
11 39 (average age) Mean: 11.2 weeks Retrospective Cohort Grade C 
Cyclosporin oral rinse 
(100mg/ml,  5ml ) 
Signs and symptoms 
improved   50% in 
64% of patients 
Table 2. Study reports on the use of topical applications in management of oGVHD.
BD = Twice daily, DEX = Dexamethasone, TAC = Tacrolimus.
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cal use of azathioprine (17) and seven case reports of the 
use of topical tacrolimus (18-24) (Table 4). These were 
excluded as they did not fulfil the SBU criteria.
With regards to the scales used for disease assessment 
in the selected studies, the majority were based on the 
National Institutes of Health consensus for GVHD to 
assess the clinical stage of oral manifestations as well as 
response to treatment (10-12,14,16). Activity of the dis-
Author/
Country/Year Topical formulation Side effects 
Elad et al
Israel/Germany 
2012
3mg budesonide/ 10 ml mouthrinse Gastrointestinal disorders (cheilitis, oesophagitis), oral 
candidosis, taste alteration 
Sari et al 
Turkey 
2007
3mg budesonide/10 ml mouthrinse One complaint of local oral burning sensation
 Park et al 
South Korea 
2013
Budesonide 0.03%, 10ml mouthrinse vs 
dexamethasone 0.01% mouthrinse 5-10ml 
Budesonide: 4 patients had oral candidosis, 1 complained 
of bitterness/astringency sensation 
Dexamethasone: 1 patient had oral candidosis, 2 patients 
complained of bitterness/astringency sensation, 2 patients 
described local oral dryness
Noce et al 
Brazil 
2014
Clobetasol propionate 0.05%, 5ml 
mouthrinse vs dexamethasone 0.1mg/ml, 
5ml  mouthrinse  
Clobetasol: one patient reported burning sensation
Dexamethasone: one patient reported burning sensation
Mawardi et al
USA 
2010
Dexamethasone (0.25mg/2.5ml)/
tacrolimus (0.25mg/2.5ml). Total 5ml 
mouthrinse
4 patients had increased tacrolimus serum peak levels but 
none exceeded the upper therapeutic range limit 
Albert et al
Germany 
2007
Tacrolimus 0.1% ointment BD orally  1. Local oral burning sensation 
2. ‘Odd sensation’ after intake of food 
3. Systemic exposure (increased plasma levels) in 4 out of 
6 patients – 1 case related to accidental over dosage
Epstein et al
Canada
1994
Ciclosporin oral rinse (100mg/ml, 5ml ) Blood levels of ciclosporin increased significantly in 2 
patients. No toxicity was observed
Table 3. Reported side effects.
Author/
Country/Year 
Sample 
size 
Age (years) 
(median/mean) 
Length of study/ Follow 
up period Topical formulation 
Eckardt et al
Germany, 2004 
3 23, 41, 63 8 weeks 
/
14 weeks 
Tacrolimus 0.1% ointment BD orally  
Sanchez et al
USA, 2004 
1 51 2 months Tacrolimus 0.1% ointment TDS orally 
Conrotto et al
Italy, 2006 
1 55 2 weeks 
/
3 months 
Tacrolimus 0.1% ointment BD orally 
Fricain et al
France, 2007 
3 41 
58
61
2 months 
>1 month 
3 months 
/
7 months 
1 year 
1 year 
Tacrolimus 0.1% ointment BD orally
Rojas et al 
Chile, 2009 
1 17 Response to treatment 
7 days 
Tacrolimus 0.1% ointment TDS orally 
Brown et al 
USA, 2013 
1 41 4 weeks 
/
14 months 
Tacrolimus 0.1% ointment BD applied 
onto custom trays
Conrotto et al
Italy, 2014 
1 63 2 months Tacrolimus 0.1% ointment BD orally 
Epstein et al
Israel/Canada/ 
USA, 2001 
8
      6   
With oral 
GVHD 
38.5 (mean age) Mean follow up 16 weeks Topical azathioprine rinse 5 mg/mL . 
Rinse 5 mL TDS-QDS for over 1 
minute and to expectorate. 
Azathioprine gel (5 mg/mL) in 3% 
methylcellulose base  
Table 4. Table of case reports and case series studies: topical applications in patients with oGVHD. 
BD = Twice daily; TDS = Three times daily; QDS = Four times daily.
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ease was classified based on the oral mucosa rating sca-
le (OMRS) (10,11) and clinical response graded under 
complete response, partial response, stable disease or 
progression (15,16). In some cases, the disease was cat-
egorised into 3 stages; mild, moderate or severe (13) and 
response to treatment labelled as “objective response as 
an improvement of at least 50% at the final/ withdrawal 
visit (compared to baseline) in the OMRS” (10). 
Subjective evaluation of symptom severity as well as 
the use of visual analogue scale (VAS) for patient’s self-
reporting for oral pain was also used (11,12,16). Albert 
et al. (14) assessed response at baseline and at each visit 
by asking for subjective evaluation of symptom sever-
ity (pain, burning, and discomfort) and by inspection 
of the oral cavity, assessing the response as complete 
response, very good partial response, partial response, 
and non-response. Epstein and Reece (12) evaluated the 
oral cavity based on the presence of erythema, lichenoid 
patterns and ulceration, including calculation of the size 
of any ulcers and the total area of ulceration. 
Multiple sources of bias were found in the clinical trials 
(10,11) such as the lack of adequate description of ran-
domisation. There was a lack of information on who was 
responsible for generating the randomisation, allocation 
concealment,  assigning participants to interventions, and 
whether the clinician responsible for the clinical assess-
ment was blinded (10,11). Both studies reported outcomes 
listed in the methods section and both applied power of 
the study (10,11). However, both reported limitations of a 
small sample size, and possible confounding factors such 
as concomitant immunosuppressive therapies and the du-
ration of topical therapy. In the cohort studies there was a 
lack of blinding of providers, participants and assessors. 
Furthermore, intention to treat analysis and power were 
not used (12-16).
Although Albert et al. (14) reported good tolerability 
and safety as well as potent activity of topical tacrolimus 
ointment in 6 paediatric patients, their study had many 
limitations due to the small size and its non-compara-
tive nature. Their response criteria lacked reliability as 
there was no explanation of who interpreted the results 
or whether there was more than one rater leading to pos-
sible observational bias. In addition, there was no stand-
ardised response criteria used at the time of the study, 
no statistical analysis of results, and possible confound-
ing factors were not identified nor addressed. 
Mawardi et al. (13) recognised a possible selection bias 
in their inclusion criteria, such as the selection of severe/
refractory cases only of oral cGVHD. This study aimed 
to describe the clinical outcomes of combined dexam-
ethasone and tacrolimus topical rinses in the manage-
ment of patients with symptomatic oral cGVHD. Poten-
tial confounders and effect modifiers were not clearly 
defined, and there was a lack of standardisation in the 
application of the oral solution with its frequency rang-
ing between twice and four times daily amongst patients 
included in the study.
Sari et al. (16) designed a retrospective study accord-
ing to NIH consensus criteria comparing the use of 
topical budesonide plus systemic therapy (prednisolone 
and ciclosporin) compared to those receiving systemic 
therapy alone. Their results suggested that there may be 
a potential benefit in the use of topical budesonide as 
an adjuvant to systemic therapy. This study lacked ran-
dom allocation and potential confounding factors were 
not taken into account, hence there were no adjustments 
to the statistical analysis. The authors commented on 
this limitation and suggested further studies where ran-
domisation and larger groups should be considered. 
Epstein & Reece (12) trial was based on the use of oral 
ciclosporin rinses in patients with cGVHD who were 
not responding to systemic therapy and dexamethasone 
oral rinses, concluding that this may be a possible coad-
juvant in refractory cases. However, without the use of 
standardised response criteria at the time of the study, 
it is difficult not to interpret the results with caution. 
The lack of blinding, power sample size, description of 
the statistical analysis of the results, and no effort to 
address potential sources of bias limit the impact and 
application of this study. 
Park et al. (15) compared the efficacy of topical budeso-
nide relative to dexamethasone treatment, with there 
being no statistical differences found between the two 
groups. This was a well-structured study where statisti-
cal analysis of the results were reported and interpreted 
appropriately. Unfortunately, this study had no power 
calculation and possible confounders were not adjusted 
for. Finally there was the limitation of a short follow up 
period in this study.
We present a resume of the effectiveness of the topical 
interventions used in the selected studies:
Randomised clinical trials:
There were two clinical trials included in this review, 
neither study included a control group, one study evalu-
ated the effectiveness of budesonide mouthwash (10) 
and the other compared the effectiveness of clobetasol 
propionate mouthwash vs dexamethasone mouthwash 
(11). A third trial will also be mentioned despite being 
presented as a letter to the editor evaluating the use of 
topical thalidomide gel (25). 
Elad et al. 2012 (10) in a double blind clinical trial, di-
vided 18 participants into four groups that used budeso-
nide 3mg as a mouthwash twice daily for 5 or 10 minutes 
compared to two other groups who used the mouthwash 
three times daily for either 5 or 10 minutes. The partici-
pants enrolled all completed the 8 week study period. 
The oral lesions improved in all patients, but the rate 
of objective improvement (defined as ≥50%) and pain 
reduction was not significantly different between the 4 
study arms (P <0.05).  
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Noce et al. 2014 (11) in an open randomised trial, en-
rolled 32 participants who were divided between study 
groups that received either clobetasol propionate (0.05%) 
mouthrinse or dexamethasone (0.1mg/5ml) mouthrinse. 
The median length of the study was 471 days. The use 
of clobetasol propionate (0.05%) resulted in a significant 
reduction in the oral mucosa rating scale total score (P 
= 0.04) and in the ulcer score (P = 0.03) when compared 
with topical dexamethasone. In both groups, there was 
significant symptomatic improvement but the response 
was significantly greater in the clobetasol group (P =0 
.02). 
John et al. 2013 (25) reported a phase II, randomised, 
placebo-controlled, double-blind clinical trial as a letter 
to the editor. When including this study for analysis us-
ing the 3 point grading system, the amount of informa-
tion was restricted and therefore did not allow for fair 
grading. They recruited 10 participants and compared 
the use of topical thalidomide 20mg gel against a placebo 
controlled group in patients with oGVHD. The length of 
the study was 4 weeks, with an 8 week follow up period. 
Only 6 subjects completed the study, 3 in each group. 
The authors recognised the small sample size precluded 
statistical confirmation of topical thalidomide’s efficacy 
in the management of oral ulcerative cGVHD, They 
also considered that the placebo effect of the Orabase 
plain product and/or the waxing and waning nature of 
cGVHD might impact on their findings. Overall, there 
was a 66% mean percentage decrease in the total sur-
face area of oral ulceration at week 4 compared with 
the baseline presentation. It was also observed that the 
TNFα levels in saliva and ulcer exudates decreased with 
therapy but with no significant difference in the salivary 
levels of  TNFα compared with baseline in both thalido-
mide (P=1.0) and placebo (P=0.109) groups. However, 
there was a decrease in salivary IL6 concentration in 
the thalidomide group (P=0.465) when compared with 
the baseline, with no decrease in the placebo group. 
- Cohort studies:
Park et al. 2013 (15) enrolled 50 participants, dividing 
them into two groups and compared the use of budeso-
nide 0.03% oral rinse with 0.01% dexamethasone rinse. 
All participants completed the one month study period. 
No statistical difference in the response was noted be-
tween the two groups (p = 0.093).  However, recently, 
in 2014, Zadik et al. (26),  carried out a re-analysis of 
the reported data, excluding patients with a (NIH) con-
sensus criteria score of 1 and 2, considered not to be 
fully eligible for topical steroids, and a further statisti-
cal analysis revealed a significantly better response to 
budesonide than to dexamethasone (p = 0.015). 
Albert et al. 2007 (14) recruited six children (aged 6-16 
years) and presented a cohort study reporting the re-
sponses of children treated with topical tacrolimus 0.1% 
ointment. The first response to treatment was docu-
mented after a median of 21 (range 6-31) days. The fol-
low up period ranged from 16 to 354 days. A complete 
response was achieved in two of the six patients with a 
partial response in the remaining four patients. 
Mawardi et al. 2010 (13) enrolled 14 subjects looking at 
the efficacy of combined topical dexamethasone (DEX) 
and tacrolimus (TAC) solutions in the management of 
oral cGVHD.
The median length and follow up of the study was 60 
days. The study showed a median improvement in the 
NIH total score at the second follow up visit (range from 
2 to 6, P=0.06), though unchanged at the first follow up 
(range from 2 to 5, P=0.41). Both erythema and lichenoid 
feature scores demonstrated a statistically significant im-
provement at the second follow up. Mawardi et al. (13) 
recognised the selected cases could be biased by the type 
of disease that they could include in the study. 
Epstein and Reece 1994 (12) recruited 11 participants 
and evaluated the use of ciclosporin A (100mg/ml) ad-
ministered as an oral rinse (5ml) in patients with ac-
tive oral lesions, despite the concurrent use of systemic 
immunosuppressants plus topical dexamethasone. The 
mean length of the study was 11.2 weeks. The study 
showed an improvement in ulceration of ≥ 50% in 7 of 
11 patients (64%) treated with the addition of topical 
ciclosporin A. 
Sari et al. 2007 (16) divided 23 participants into two 
groups of which one group received topical budesonide 
(3mg in 10 ml) oral rinse in addition to systemic therapy 
(prednisone and ciclosporin) (Group A, n = 12), com-
pared to another group of subjects who were adminis-
tered the systemic therapy alone (Group B, n = 11). The 
median length of the study was 8.5 months and 7 months 
for groups A and B respectively. The median follow up 
period was 108 days for group A and 120 days for group 
B. There was an overall clinical response rate of 83% 
and 36% for groups A and B, respectively (P = 0.036). 
However, no statistically significant differences were 
found between median pain scores of the two groups 
before and after treatment (P = 0.740 and P = 0.091).
 
Discussion
Based on this systematic review, the number of ran-
domised clinical trials reporting the use of topical ster-
oids or immunosuppresants in the management of the 
inflammatory mucosal lesions encountered in oGVHD 
appears to be very low. Using the Swedish Council on 
Technology Assessment in Health Care and the Centre 
for Reviews and Dissemination, University of York 3- 
point grading system, there is limited evidence to sup-
port these therapies based on the analysed papers.  The 
reported studies presented different lengths of follow 
up and also differently scaled schemes of assessment of 
outcome. The sample sizes were generally small, how-
ever both clinical trials provided a statistical power of 
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80%, a commonly accepted value (10,11). In all of the 
selected studies it is not recorded whether the outcome 
assessors were blinded when assessing the response 
to treatment. This bias could have been prevented by 
ensuring outcome assessors are blind to treatment al-
location, for example by using independent clinicians 
who are not otherwise involved in the trial to assess 
patients, or using a blinded adjudication committee to 
determine the outcome (27). However, the nature of the 
study can preclude  this, as reported by Kahan et al. 
(28) who reported that a “blinded outcome assessment 
may not always be feasible due to the nature of the trial, 
for example, when all researchers in a centre are aware 
of treatment allocation, or relevant clinical information 
cannot be sent to a blinded assessor”. 
Currently, the literature search in systematic reviews 
and the quality assessment of included studies are well-
established processes in evidence-based medicine and 
dentistry (29). However, the precise methods for the 
process can differ among various systematic reviews 
(7). Meier et al. (6) (2011), provided a review of topi-
cal applications used for GVHD. We believe this new 
systematic review could provide new data, acknowledg-
ing observational studies as well as clinical trials. We 
included five cohort studies in addition to two clinical 
trials based on the SBU guideline. We acknowledge that 
one of the limitations of this review is that the search 
methodology/parameters used in this review cannot 
guarantee that all articles pertinent to the topic were 
included; other databases may include information in 
this field. Apart from English, we included Portuguese 
and Spanish language studies, however we acknowl-
edge that searches including other languages may have 
returned relevant articles and further reviews including 
other languages might be considered. 
A notable finding was the lack of randomised controlled 
trials in the effectiveness of topical therapy in the man-
agement of oGVHD. The randomised controlled trial is 
acknowledged to be the most powerful tool to evalu-
ate the effectiveness of treatment and the quality of the 
study significantly affects the validity of the conclusions 
drawn (9). John et al. (25) showed thalidomide (20mg 
gel) was effective in individuals with oral cGVHD, al-
though the authors did recognise the potential influence 
of the small size of the sample in the reporting of their 
results. As this was presented as a ‘letter to the editor’, 
there was a lack of detailed description of randomisa-
tion, allocation, concealment and blinding, and as such 
the conclusions drawn from these data need to be inter-
preted with caution. However, we felt that the nature of 
this study was relevant to this review and as such its in-
clusion was warranted.  The lack of randomised control 
trials on this topic could be due to practical difficulties 
secondary to the nature of patients with oGVHD, which 
can raise both ethical and logistical issues.
The majority of the studies had a cohort design includ-
ing two retrospective cohorts and two prospective co-
horts.  From an evidence-based point of view, the sci-
entific value of a retrospective study is limited although 
some authors have argued that well-designed prospec-
tive or retrospective studies should not be ignored when 
assessing the available scientific literature (8).  
The majority of patients in the selected studies were also 
taking systemic medications along with the topical ap-
plication studied. The intention was to analyse the effect 
of the topical applications on the disease. As a result it is 
difficult to ascribe any improvements described to the 
systemic medication or the topical therapies. As such 
these results should be interpreted with caution. Dilger. 
et al. (30) report that in patients with oral cGVHD, 10% 
of the topical dose of budesonide can enter the circula-
tion, possibly due to the loss of epithelial integrity that 
can occur in ulcerative lesions in oGVHD and metabo-
lisation. When compared with the systemic concentra-
tions attained after the oral intake of enteric-coated 
budesonide for inflammatory bowel diseases, the levels 
reported are within recognised safety thresholds.
A multicentre questionnaire undertaken by Elad et al. 
(31) regarding the treatment of oral cGVHD showed 
that steroids were the first-line topical management 
of choice (91.7 %). The topical steroids budesonide 
(3mg/10ml) and dexamethasone (0.1mg/5ml) were the 
most commonly studied. Tacrolimus (TAC) was stud-
ied as a single topical application or in combination 
with dexamethasone. TAC bonds to the immunophilin 
FK506 binding protein, inhibiting calcineurin phos-
phatase. It inhibits calcium-dependent events, such as 
interleukin-2 gene transcription, nitric oxide synthase 
activation, cell degranulation, and apoptosis (32). 
With regards to the side effects and safety, a cohort 
study undertaken by Mawardi et al. (13) found that 
when topical DEX and TAC were used in combination, 
4 patients (37%) had increased TAC serum peak levels 
that corresponded with the application of topical treat-
ment. Following the use of topical TAC, many reports 
have raised concerns on the clinically significant eleva-
tion of tacrolimus serum levels (13,22). Some case re-
ports have shown elevated levels of TAC although the 
actual absorption via the oral mucosa remains ambi-
guous (14,22). A retrospective study by Thomson et al 
(33) described the safety of TAC when used to treat in-
dividuals with erosive lichen planus. They noted minor 
local side effects but an absence of evidence of systemic 
absorption. 
As has been frequently reported there is an increased 
risk of oral malignancy in oral GVHD (5), although to 
our knowledge, this increased risk of malignancy has 
not been associated with the use of topical tacrolimus 
in cases of oral GVHD. Another calcineurin inhibi-
tor; ciclosporin, has been studied for the treatment of 
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continuous oral ulceration used as both a topical and 
systemic agent. Epstein & Reece (12) showed improve-
ments in oGVHD using topical ciclosporin. Many stud-
ies on mucosal inflammatory conditions such as lichen 
planus did not report improved outcomes with the use of 
this calcineurin inhibitor when compared with topical 
steroids (34). The appropriate follow up time to assess 
the response to treatment is debatable, particularly with 
regards to the monitoring of potential oral malignancy 
(35). The increased risk of secondary malignancies is a 
major late complication of HSCT. A study showed that 
2-6% of post-HSCT patients had developed a second-
ary solid tumour within 10 years (35). Approximately 
one-third of these secondary solid tumours were sq-
uamous cell carcinomas (SCCs) of the skin or the oral 
cavity. The oral cavity accounted for up to half of the 
SCC cases alone. Development of malignancy was not 
reported during the short length of the included studies 
and longer follow up periods could be considered with 
this in mind. Curtis et al. (36) reported that in 16 cases 
of oral SCC associated with oGVHD, the most frequent 
site of SCC was the tongue, followed by the lips, and 
gingivae. From the 16 cases, 11 had received immuno-
suppressive drugs for two or more years and the risk of 
SCC in the oral cavity appears to be higher in patients 
who have undergone HSCT. 
The use of budesonide has also been studied by Elad 
et al. in an open label trial (37), involving twelve pa-
tients diagnosed with chronic and resistant oral GVHD. 
They were managed with topical budesonide (3 mg /5 
ml saline) 2 to 3 times a day for up to 3 months. Their 
findings showed that 7 of the 12 patients had scores of 
“good” or “complete” recovery following evaluation by 
the examiner and assessment of the subject.  In some 
patients in this study, the systemic management with 
both prednisolone and ciclosporin was gradually re-
duced as early as 2 weeks following the commencement 
of budesonide mouthwashes. The authors stated that 3 
examiners were used to carry out the clinical exami-
nations and recognised that inter-observer calibration 
was not implemented. Van Schandevyl et al. (38) have 
presented a protocol where budesonide mouthwash was 
used as an adjuvant (Budenofalk® 3 mg gastro-resistant 
capsules) and results of a large-scale, phase III, ran-
domised, controlled, double-blinded multicenter study 
assessing this new preparation of topical budesonide for 
the treatment of oral cGVHD is awaited.
Noce et al. (11) compared the use of topical clobetasol 
with dexamethasone, demonstrating significant symp-
tomatic improvements over baseline in both groups, 
but with the response being significantly greater in the 
clobetasol group. The authors recognised the limita-
tions of this study such as the small number of patients 
enrolled and other confounding variables, and suggest-
ed that further studies with larger samples and subject 
stratification, taking into account the influence of these 
variables on the topical therapy for oral cGVHD le-
sions, might be considered. Erosive oral lichen planus 
(OLP) has close similarities in its disease presentation 
to oGVHD. It is therefore pertinent to consider what 
topical treatments are used for the management of ero-
sive OLP. In a Cochrane review of topical applications 
for the treatment of oral lichen planus, the authors con-
cluded there is no evidence that any one topical steroid 
is more effective than another (39). Different treatment 
regimens using clobetasol have been proposed in the lit-
erature (40). Previous studies have used 0.05% topical 
clobetasol applications, 2 or 3 times a day, for a period 
between 2 weeks and 2 months (11,39,40). Topical dex-
amethasone has been used in a 1 mg/mL solution or in 
a 0.043% paste, 3 to 4 times a day, for 1 month (11). Re-
ported symptomatic improvement of erosive oral lichen 
planus lesions varied from 63.6% to 100% with topi-
cal clobetasol, and from 38.50% to 72.51% with topical 
dexamethasone (11,39,40).
Budesonide was potentially linked to some side ef-
fects including gastrointestinal tract disorders (cheili-
tis, oesophagitis), oral candidosis and taste disturbance 
(10). Similar findings of side effects were reported in 
other studies using budesonide, as well as oral burning 
sensations (15,16,37). In studies where dexamethasone 
mouth rinse was used, side effects were reported in-
cluding oral burning sensations, oral candidosis, local 
dryness and bitterness/astringency sensations (11,15). A 
local oral burning sensation was reported by one patient 
using topical clobetasol propionate (11) (Table 2).
In conclusion, the evidence for the use of topical thera-
pies in the management of the inflammatory mucosal le-
sions encountered in oGVHD is limited and the results 
of this review should be interpreted with some caution. 
Oral GVHD is a very debilitating condition particularly 
with respect to the effect on quality of life (QOL). We 
suggest that high quality randomised controlled trials of 
the effectiveness of topical therapies in oGVHD, with 
good statistical power and standardised outcome meas-
ures are needed to establish the effectiveness of both 
established and novel therapies in order to allow the 
development of clinical guidelines for the topical man-
agement of the inflammatory mucosal lesions found in 
oGVHD.
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